In this podcast, the team of Therapeutics Initiative reviews the pharmacological and non pharmacological treatments for osteoarthritis.
“In our 32nd episode we review the therapeutic options for the treatment of osteoarthritis. We first deal with lifestyle interventions for osteoarthritis. We consider the pain pharmaceuticals like acetaminophen, topical or oral NSAIDs, and opiates as well as some of the other osteoarthritis therapies such as glucosamine or steroid injections”.
Drugs related to this osteoarthritis treatment podcast:
Salicylates: Acetylsalicylic acid (Aspirin), Amoxiprin, Benorylate/Benorilate, Choline magnesium salicylate, Diflunisal, Ethenzamide, Faislamine, Methyl salicylate, Magnesium salicylate, Salicyl salicylate, Salicylamide.
Arylalkanoic acids : Diclofenac, Aceclofenac, Acemethacin, Alclofenac, Bromfenac,
Etodolac, Indomethacin, Nabumetone, Oxametacin, Proglumetacin, Sulindac, Tolmetin.
2-Arylpropionic acids (profens): Ibuprofen, Alminoprofen, Benoxaprofen (withdrawn from the market), Carprofen, Dexibuprofen, Dexketoprofen, Fenbufen, Fenoprofen, Flunoxaprofen, Flurbiprofen, Ibuproxam, Indoprofen, Ketoprofen (Actron, at least, has been withdrawn from the market.), Ketorolac, Loxoprofen, Naproxen, Oxaprozin, Pirprofen, Suprofen, Tiaprofenic acid
N-Arylanthranilic acids (fenamic acids): Mefenamic acid, Flufenamic acid, Meclofenamic acid, Tolfenamic acid
Pyrazolidine derivatives: Phenylbutazone, Ampyrone, Azapropazone, Clofezone, Kebuzone, Metamizole, Mofebutazone, Oxyphenbutazone, Phenazone, Sulfinpyrazone
Oxicams: Piroxicam, Droxicam, Lornoxicam, Meloxicam, Tenoxicam
COX-2 inhibitors: Celecoxib (FDA alert), Etoricoxib (FDA withdrawn), Lumiracoxib TGA cancelled registration, Parecoxib FDA withdrawn, Rofecoxib (withdrawn from market), Valdecoxib (withdrawn from market )
Sulphonanilides: Nimesulide (banned by several countries for the potential risk of hepatotoxicity)
Oxycodone, Codeine, Morphine, Tramadol.
Others: Acetaminophen, Glucosamine sulfate, Rubefacients